INSYS Therapeutics, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2018. For the quarter, the company reported net revenue of $16,357,000 against $31,485,000 a year ago. Loss from operations was $48,966,000 against $20,661,000 a year ago. Net loss was $46,293,000 against $45,927,000 a year ago. Basic loss per share was $0.62 against $0.63 a year ago. For the year, the company reported net revenue of $82,080,000 against $140,693,000 a year ago. Loss from operations was $127,723,000 against income of $219,031,000 a year ago. Net loss was $124,507,000 against income of $226,835,000 a year ago. Basic loss per share was $1.68 against $3.12 a year ago.